Bapineuzumab in subject with mild to moderate Alzheimer's Disease who are APOEe4 carriers.
Qualified Participants Must:
Be 50 to 88 years of age
Have a diagnosis of probable Alzheimer's Disease
Have a caregiver who is willing to be involved in the study with you
Be able to attend 15 study visits during an 83-week period
Qualified Participants May Receive:
At no charge, the investigational drug, physical exams, and laboratory services and tests. Throughout the study, participants will be monitored by a medical team including a nurse or study coordinator and a physician.